For the second year in a row, GEN spoke with David Barrett, JD, who has been the CEO of ASGCT since 2016. In this interview, we discuss his perspective on the event, if there is anything new that ...

At ASGCT, the company will share data showing that its RNA achieves higher, more durable protein expression compared to other ...

The FDA has granted accelerated approval to Regeneron Pharmaceuticals’ Otarmeni™ (lunsotogene parvec-cwha) as the first gene ...

Enein, MD, PhD, for a measurement-driven approach that advances cell therapy translation, from high-dimensional analytics to ...

Macrophages use cell‑volume changes to sense danger, reprogram gene expression, and heighten inflammatory and antiviral responses.

Researchers say identified mAbs could represent “a basis to develop a treatment that is urgently needed as measles virus ...

There has been widespread success in treating blood cancers, while progress in solid tumors has been more limited.

The data shows that the drugs triggered activity in the central amygdala that reduced dopamine release into the brain's reward circuitry.

Bayer has agreed to acquire Perfuse Therapeutics for up to $2.45 billion, in a deal designed to broaden the buyer’s ophthalmology pipeline with Perfuse’s sole pipeline drug and two clinical phase ...

Last month, the AGBT Agricultural Meeting was held in Phoenix, Arizona. The conference is focused on agricultural genomics—plant and animal genetics. During the meeting, the recipients of the 2026 ...

This eBook brings together perspectives from Genetic Engineering News and ElevateBio to examine both the technical and ...

UCB has agreed to acquire Candid Therapeutics for up-to-$2.2 billion, in a deal designed to expand the buyer’s presence in ...